Exemplos de uso de To patients with normal renal function em Inglês e suas traduções para o Português
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
It is important to highlight that such warning does not apply to patients with normal renal function.
Compared to patients with normal renal function, the AUC for Losartan is about 2-times higher in haemodialysis dialysis patients. .
The pharmacokinetics of abacavir in patients with end-stage renal disease is similar to patients with normal renal function.
Hdmtx can be safely administered to patients with normal renal function by the use of alkalinization, hydration and pharmacokinetically guided lv rescues.
The serum half-life of lincomycin may be prolonged in patients with severe impairment of renal function, compared to patients with normal renal function.
When administered to patients with normal renal function in the absence of other factors, both contrast agents high and low osmolality had the same risk of nephrotoxicity.
In the PsA or PSOR clinical studies,the safety profile observed in patients with mild renal impairment was comparable to patients with normal renal function.
The pharmacokinetics of abacavir in patients with end-stage renal disease is similar to patients with normal renal function, and, therefore, no dose reduction is required in patients with renal impairment.
Pharmacokinetic studies with doxazosin in patients with renal impairment also showed no significant alterations compared to patients with normal renal function.
After a 5 day treatment of repaglinide(2 mg x 3/day) in patients with a severe impaired renal function(creatinine clearance: 20-39 ml/min.), the results showed a significant 2-fold increase of the exposure(AUC) and half-life(t1/2)as compared to patients with normal renal function.
Plasma level monitoring in a Phase III clinical study showed that levels of total silodosin after 4 weeks of treatment did not change in patients with mild impairment(n=70),compared to patients with normal renal function(n=155), while the levels were doubled on average in patients with moderate impairment n=7.
Furthermore in the clinical studies, patients on a sulphonylurea combination,with mild renal impairment had an increased incidence of hypoglycaemia compared to patients with normal renal function.
No overall differences in safety of Zurampic were observed in patients with mild or moderate renal impairment(eCrCL of 30-89 mL/min)compared to patients with normal renal function see sections 4.2 and 5.2.
The increased dose interval for Truvada in patients with moderate renal impairment is expected to result in higher peak plasma concentrations andlower Cmin levels as compared to patients with normal renal function.
Peak plasma levels of empagliflozin were similar in subjects with moderate renal impairment andkidney failure/ESRD compared to patients with normal renal function.
Population PK modeling indicates that exposure approximately doubles in patients with severe renal impairment(CrCL 15- 29 mL/min)relative to patients with normal renal function.
Pharmacokinetic studies with doxazosin in patients with renal impairment also showed no significant alterations compared to patients with normal renal function.
In a renal impairment study AUC of enfuvirtide was increased on average by 43-62% in patients with severe orend stage renal disease compared to patients with normal renal function.
The effect of renal impairment on the clearance of pembrolizumab was evaluated by population pharmacokinetic analyses in patients with mild ormoderate renal impairment compared to patients with normal renal function.
Mean normalized AUC exposure to pomalidomide was 98.2% with a 90% confidence interval[77.4% to 120.6%] in moderate renal impairment patients(eGFR≥30 to≤45mL/minute/1.73 m2)compared to patients with normal renal function.
Mean normalized AUC exposure to pomalidomide increased by 35.8% with a 90% CI[7.5% to 70.0%] in severe renal impairment patients requiring dialysis(CrCl< 30mL/minute requiring dialysis)compared to patients with normal renal function.
Available clinical data and physiology-based pharmacokinetic modelling indicate similar steady-state exposure of regorafenib and its metabolites M-2 and M-5 in patients with mild andmoderate renal impairment compared to patients with normal renal function.
Although this study presented some limitations(i.e., unbound drug concentrations not studied), results suggested that the atazanavir pharmacokinetic parameters were decreased by 30% to 50% in patients undergoing haemodialysis compared to patients with normal renal function.
Mean normalized AUC exposure to pomalidomide was 100.2% with a 90% confidence interval[79.7% to 127.0%] in severe renal impairment patients not requiring dialysis(CrCl< 30 or eGFR< 30 mL/minute/1.73 m2)compared to patients with normal renal function.
Population pharmacokinetic analyses showed that the pomalidomide pharmacokinetic parameters were not remarkably affected in renally impaired patients(defined by creatinine clearance or estimated glomerular filtration rate[eGFR])compared to patients with normal renal function CrCl≥60 mL/minute.
Population pharmacokinetic analyses showed that alirocumab exposure(AUC0-14d) at steady state at both the 75 and 150 mg Q2W dosing regimen was increased by 22%-35%, and 49%-50% in patients with mild and moderate renal impairment, respectively,compared to patients with normal renal function.
A review of safety data of patients enrolled in all clinical studies does not indicate that mild renal impairment(n=487) poses an additional safety risk during silodosin therapy(such as an increase in dizziness or orthostatic hypotension)as compared to patients with normal renal function n=955.